Glycosaminoglycan inhibitor and promoter

Abstract

The purpose of the present invention is to develop a medicine for diseases related to glycosaminoglycan functions with less side effects. Provided is a glycosaminoglycan inhibitor or promoter that comprises lactoferrin or a derivative thereof.

1 - 8 . (canceled) 
     
     
         9 . A method for treating a glycosaminoglycan-related disease or condition, comprising administering lactoferrin or a derivative thereof to a patient or subject in need of treatment. 
     
     
         10 . The method according to  claim 9 , wherein the lactoferrin is iron free (Apo) or iron saturated (Holo) lactoferrin, prepared in an amount from 0.001 to 10 g/kg/day. 
     
     
         11 . The method according to  claim 9 , wherein the lactoferrin is of human origin. 
     
     
         12 . The method according to  claim 9 , wherein the lactoferrin is a protein or peptide selected from the group consisting of (a) to (d) below:
 (a) a protein consisting of any one amino acid sequence of SEQ ID NOS: 1-6;   (b) a protein comprising N-lobe of lactoferrin;   (c) a protein consisting of the amino acid sequence in which 1 to 70 amino acids are deleted, substituted, inserted, and/or added in any one amino acid sequence of SEQ ID NOS: 1 to 6, and which has activity to inhibit or promote the function of glycosaminoglycans; and   (d) a protein consisting of the amino acid sequence having 90% or more sequence identity to any one amino acid sequence of SEQ ID NOS: 1-6 and having activity that inhibits or promotes the expression or function of chondroitin sulfate.   
     
     
         13 . The method according to  claim 9 , wherein the derivative of the lactoferrin is a hinge deletion human lactoferrin/human IgG Fc fusion protein (hLF-CH2-CH3) (SEQ ID NO: 9), human lactoferrin/human serum albumin fusion protein (hLF-HSA) (SEQ ID NO: 10) or human lactoferrin-human granulocyte colony-stimulating factor (G-CSF) fusion protein (hLF-G-CSF) (SEQ ID NO: 11). 
     
     
         14 . The method according to  claim 9 , wherein the glycosaminoglycan is chondroitin sulfate-C(CS-C), chondroitin sulfate-D (CS-D), or chondroitin sulfate-E (CS-E). 
     
     
         15 . The method according to  claim 9 , for use in combination with chondroitin sulfate-degrading enzymes. 
     
     
         16 . The method according to  claim 9 , wherein the disease is any one selected from the group consisting of spinal cord injury, cancer metastasis, cancer, diabetes, inflammation, atherosclerosis, multiple sclerosis, fibrosis, acute respiratory disease, and Alzheimer's disease. 
     
     
         17 . (canceled) 
     
     
         18 . The method according to  claim 9 , which the administration is made in the form of an injection. 
     
     
         19 . The method according to  claim 9 , wherein the administration is an oral administration.